Skip to main content
SpringerLink
Log in
Book cover

Handbook of Parathyroid Diseases pp 141–158Cite as

Secondary Hyperparathyroidism

  • Chapter
  • First Online:

Abstract

Parathyroid hormone (PTH) is an 84 amino acid polypeptide produced by the chief cells of the parathyroid gland, and its primary role in human physiology is the maintenance of normal extracellular fluid-ionized calcium (Ca2+) concentration. PTH secretion rises in response to a low Ca2+. Under high Ca2+ conditions, PTH secretion is reduced, and intracellular degradation of PTH increases, with resultant increased proportional secretion of biologically inactive fragments of PTH. The influence of secreted fragments of PTH on the measurement of serum PTH is discussed in Chap. 3.

Naifa Lamki Busaidy and Amit Lahoti contributed equally to this work

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Ritter CS, Armbrecht HJ, Slatopolsky E, et al. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int. 2006;70:654–9.

    Article  PubMed  CAS  Google Scholar 

  2. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.

    Article  PubMed  CAS  Google Scholar 

  3. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945–53.

    Article  PubMed  CAS  Google Scholar 

  4. Krajisnik T, Bjorklund P, Marsell R, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007;195:125–31.

    Article  PubMed  CAS  Google Scholar 

  5. Silver J, Naveh-Many T. FGF23 and the parathyroid glands. Pediatr Nephrol. 2010;25: 2241–5.

    Article  PubMed  Google Scholar 

  6. Slatopolsky E, Caglar S, Pennell JP, et al. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest. 1971;50:492–9.

    Article  PubMed  CAS  Google Scholar 

  7. Silver J, Naveh-Many T. Phosphate and the parathyroid. Kidney Int. 2009;75:898–905.

    Article  PubMed  CAS  Google Scholar 

  8. Brown EM, Wilson RE, Eastman RC, et al. Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab. 1982;54:172–9.

    Article  PubMed  CAS  Google Scholar 

  9. Mayer GP, Habener JF, Potts Jr JT. Parathyroid hormone secretion in vivo. Demonstration of a calcium-independent nonsuppressible component of secretion. J Clin Invest. 1976;57:678–83.

    Article  PubMed  CAS  Google Scholar 

  10. Gittes RF, Radde IC. Experimental model for hyperparathyroidism: effect of excessive ­numbers of transplanted isologous parathyroid glands. J Urol. 1966;95:595–603.

    PubMed  CAS  Google Scholar 

  11. Davies DR, Dent CE, Watson L. Tertiary hyperparathyroidism. Br Med J. 1968;3:395–9.

    Article  PubMed  CAS  Google Scholar 

  12. IOM (Institute of Medicine). Dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academies Press; 2011.

    Google Scholar 

  13. Steingrimsdottir L, Gunnarsson O, Indridason OS, et al. Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA. 2005;294:2336–41.

    Article  PubMed  CAS  Google Scholar 

  14. Adami S, Viapiana O, Gatti D, et al. Relationship between serum parathyroid hormone, vitamin D sufficiency, age, and calcium intake. Bone. 2008;42:267–70.

    Article  PubMed  CAS  Google Scholar 

  15. Rucker D, Allan JA, Fick GH, et al. Vitamin D insufficiency in a population of healthy western Canadians. CMAJ. 2002;166:1517–24.

    PubMed  Google Scholar 

  16. Gonzalez EA, Sachdeva A, Oliver DA, et al. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol. 2004;24:503–10.

    Article  PubMed  CAS  Google Scholar 

  17. Taskapan H, Ersoy FF, Passadakis PS, et al. Severe vitamin D deficiency in chronic renal failure patients on peritoneal dialysis. Clin Nephrol. 2006;66:247–55.

    PubMed  CAS  Google Scholar 

  18. Mucsi I, Almasi C, Deak G, et al. Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis. Clin Nephrol. 2005;64:288–94.

    PubMed  CAS  Google Scholar 

  19. Zehnder D, Landray MJ, Wheeler DC, et al. Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. The chronic renal impairment in Birmingham (CRIB) study. Nephron Clin Pract. 2007;107:c109–16.

    Article  PubMed  CAS  Google Scholar 

  20. Priemel M, von Domarus C, Klatte TO, et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res. 2010;25:305–12.

    Article  PubMed  CAS  Google Scholar 

  21. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584–92.

    Article  PubMed  CAS  Google Scholar 

  22. Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119:2545–52.

    Article  PubMed  CAS  Google Scholar 

  23. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol. 2009;20:1453–64.

    Article  PubMed  CAS  Google Scholar 

  24. Mathew S, Tustison KS, Sugatani T, et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol. 2008;19:1092–105.

    Article  PubMed  CAS  Google Scholar 

  25. Raggi P, Kleerekoper M. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:836–43.

    Article  PubMed  CAS  Google Scholar 

  26. Sahota O, Mundey MK, San P, et al. Vitamin D insufficiency and the blunted PTH response in established osteoporosis: the role of magnesium deficiency. Osteoporos Int. 2006;17:1013–21.

    Article  PubMed  CAS  Google Scholar 

  27. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet. 1998;351:805–6.

    Article  PubMed  CAS  Google Scholar 

  28. Heaney RP, Dowell MS, Hale CA, et al. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr. 2003;22:142–6.

    PubMed  CAS  Google Scholar 

  29. Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85:1586–91.

    PubMed  CAS  Google Scholar 

  30. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84:18–28.

    PubMed  CAS  Google Scholar 

  31. Looker AC, Pfeiffer CM, Lacher DA, et al. Serum 25-hydroxyvitamin D status of the US population: 1988–1994 compared with 2000–2004. Am J Clin Nutr. 2008;88:1519–27.

    Article  PubMed  CAS  Google Scholar 

  32. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117:503–11.

    Article  PubMed  CAS  Google Scholar 

  33. Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab. 2008;93: 677–81.

    Article  PubMed  CAS  Google Scholar 

  34. Kumar J, Muntner P, Kaskel FJ, et al. Prevalence and associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001–2004. Pediatrics. 2009;124:e362–70.

    Article  PubMed  Google Scholar 

  35. Gao P, D’Amour P. Evolution of the parathyroid hormone (PTH) assay – importance of ­circulating PTH immunoheterogeneity and of its regulation. Clin Lab. 2005;51:21–9.

    PubMed  CAS  Google Scholar 

  36. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010;341:c3691.

    Article  PubMed  Google Scholar 

  37. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1–130.

    Google Scholar 

  38. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1–201.

    Google Scholar 

  39. Jamal SA, Fitchett D, Lok CE, et al. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant. 2009;24:3168–74.

    Article  PubMed  CAS  Google Scholar 

  40. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–52.

    Article  PubMed  CAS  Google Scholar 

  41. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71:438–41.

    Article  PubMed  CAS  Google Scholar 

  42. Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008;51:952–65.

    Article  PubMed  CAS  Google Scholar 

  43. Stubbs JR, Idiculla A, Slusser J, et al. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol. 2010;21:353–61.

    Article  PubMed  CAS  Google Scholar 

  44. Al-Aly Z, Qazi RA, Gonzalez EA, et al. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis. 2007;50:59–68.

    Article  PubMed  CAS  Google Scholar 

  45. Saab G, Young DO, Gincherman Y, et al. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract. 2007;105:c132–8.

    PubMed  CAS  Google Scholar 

  46. Hamdy NA, Kanis JA, Beneton MN, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995;310:358–63.

    Article  PubMed  CAS  Google Scholar 

  47. Slatopolsky E, Berkoben M, Kelber J, et al. Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism. Kidney Int Suppl. 1992;38:S43–9.

    PubMed  CAS  Google Scholar 

  48. Rix M, Eskildsen P, Olgaard K. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant. 2004;19:870–6.

    Article  PubMed  CAS  Google Scholar 

  49. Coyne D, Acharya M, Qiu P, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006;47:263–76.

    Article  PubMed  CAS  Google Scholar 

  50. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72:1004–13.

    Article  PubMed  CAS  Google Scholar 

  51. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005;16:1115–25.

    Article  PubMed  CAS  Google Scholar 

  52. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349:446–56.

    Article  PubMed  CAS  Google Scholar 

  53. Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant. 2004;19: 179–84.

    Article  PubMed  CAS  Google Scholar 

  54. Palmer SC, McGregor DO, Macaskill P, et al. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med. 2007;147:840–53.

    PubMed  Google Scholar 

  55. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516–25.

    Article  PubMed  CAS  Google Scholar 

  56. Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003;14: 575–83.

    Article  PubMed  CAS  Google Scholar 

  57. Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium  ×  phosphorus in secondary hyperparathyroidism. Kidney Int. 2003;63: 248–54.

    Article  PubMed  CAS  Google Scholar 

  58. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005;67:760–71.

    Article  PubMed  CAS  Google Scholar 

  59. Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68:1793–800.

    Article  PubMed  CAS  Google Scholar 

  60. Chonchol M, Locatelli F, Abboud HE, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis. 2009;53:197–207.

    Article  PubMed  CAS  Google Scholar 

  61. Charytan C, Coburn JW, Chonchol M, et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis. 2005;46:58–67.

    Article  PubMed  CAS  Google Scholar 

  62. Olgaard K, Lewin E. Can hyperparathyroid bone disease be arrested or reversed? Clin J Am Soc Nephrol. 2006;1:367–73.

    Article  PubMed  CAS  Google Scholar 

  63. Komaba H, Fukagawa M. Regression of parathyroid hyperplasia by calcimimetics – fact or illusion? Nephrol Dial Transplant. 2009;24:707–9.

    Article  PubMed  Google Scholar 

  64. Lomonte C, Vernaglione L, Chimienti D, et al. Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism? Clin J Am Soc Nephrol. 2008;3:794–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrine Neoplasia & Hormonal Disorders, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1461, Houston, 77031, TX, USA

    Naifa Lamki Busaidy MD, FACP

  2. Section of Nephrology, Department of General Internal Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

    Amit Lahoti MD

  3. Department of Medicine, University of Calgary, Calgary, AB, Canada

    David A. Hanley MD, FRCPC

Authors
  1. Naifa Lamki Busaidy MD, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amit Lahoti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David A. Hanley MD, FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naifa Lamki Busaidy MD, FACP .

Editor information

Editors and Affiliations

  1. , Dept of Endocrinology and Metabolism, McMaster University, [not given], Hamilton, L8S4L8, Ontario, Canada

    Aliya A. Khan, MD

  2. Mt. Zion Medical Center, Dept. Surgery, University of California, San Francisco, Divisadero St. 1600, San Francisco, 94115, California, USA

    Orlo H. Clark

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Busaidy, N.L., Lahoti, A., Hanley, D.A. (2012). Secondary Hyperparathyroidism. In: Khan, MD, A., Clark, O. (eds) Handbook of Parathyroid Diseases. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-2164-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-2164-1_9

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-2163-4

  • Online ISBN: 978-1-4614-2164-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation